[{"id":"2af13408-f944-43dc-982b-a4a2493f0cae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05284552","created_at":"2022-03-17T11:53:02.886Z","updated_at":"2024-07-02T16:35:22.133Z","phase":"Phase 2","brief_title":"Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","source_id_and_acronym":"NCT05284552","lead_sponsor":"University Hospital, Linkoeping","biomarkers":" SELP","pipe":"","alterations":" ","tags":["SELP"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/12/2022","start_date":" 07/12/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-01-25"},{"id":"eab1a43d-7a68-468e-afa8-d76f5c50ac51","acronym":"","url":"https://clinicaltrials.gov/study/NCT05654766","created_at":"2022-12-16T14:58:27.019Z","updated_at":"2024-07-02T16:35:59.016Z","phase":"","brief_title":"Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies","source_id_and_acronym":"NCT05654766","lead_sponsor":"Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","biomarkers":" ANXA5 • ITGA2B • SELP","pipe":"","alterations":" ","tags":["ANXA5 • ITGA2B • SELP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 01/02/2023","start_date":" 01/02/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-12-16"},{"id":"31eda37b-cf5e-4994-9ab7-9193890828a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05493878","created_at":"2022-08-20T06:02:16.434Z","updated_at":"2024-07-02T16:36:05.871Z","phase":"","brief_title":"ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer","source_id_and_acronym":"NCT05493878","lead_sponsor":"Assiut University","biomarkers":" ITGA2B • SELP","pipe":"","alterations":" ","tags":["ITGA2B • SELP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 128","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2022-08-09"},{"id":"814f2e7b-64c1-4284-91fd-c6a38746efc1","acronym":"HEAL","url":"https://clinicaltrials.gov/study/NCT04133220","created_at":"2021-01-18T20:11:13.719Z","updated_at":"2024-07-02T16:36:54.391Z","phase":"","brief_title":"Endothelial Activation Hemostasis Disturbances and Severe Bleeding Events in Hyperleukocytic Acute Myeloid Leukemia","source_id_and_acronym":"NCT04133220 - HEAL","lead_sponsor":"Assistance Publique - Hôpitaux de Paris","biomarkers":" IL6 • SDC1 • CD40LG • SELP","pipe":"","alterations":" ","tags":["IL6 • SDC1 • CD40LG • SELP"],"overall_status":"Unknown status","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2019","start_date":" 10/01/2019","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2019-10-21"}]